KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $846.2 million.

  • Jazz Pharmaceuticals' Long-Term Deferred Tax rose 4508.61% to $846.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $846.2 million, marking a year-over-year increase of 4508.61%. This contributed to the annual value of $560.2 million for FY2024, which is 1724.68% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $846.2 million for Q3 2025, which was up 4508.61% from $602.9 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $846.2 million for Q3 2025, and its period low was $258.5 million during Q1 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Long-Term Deferred Tax had a median value of $430.1 million in 2023 and averaged $447.3 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Long-Term Deferred Tax increased by 9.5% in 2022, and later skyrocketed by 4743.45% in 2023.
  • Jazz Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $311.1 million in 2021, then rose by 20.94% to $376.2 million in 2022, then increased by 27.0% to $477.8 million in 2023, then grew by 17.25% to $560.2 million in 2024, then surged by 51.04% to $846.2 million in 2025.
  • Its last three reported values are $846.2 million in Q3 2025, $602.9 million for Q2 2025, and $575.1 million during Q1 2025.